Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis - PubMed
- ️Mon Jan 01 2018
Meta-Analysis
Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis
Anna Lena Lopez et al. Clin Infect Dis. 2018.
Abstract
In addition to improved water supply and sanitation, the 2-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The metaanalysis showed that an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggest otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.
Figures
Selection of reports included in the analysis.
Seroconversion after the first and second dose of a bivalent oral cholera vaccine, all age groups. Abbreviation: GMT, geometric mean titer.
Seroconversion to the Ogawa serotype after the first and second dose of a bivalent oral cholera vaccine in young children (A), children (B), and adults (C). Abbreviations: CI, confidence interval; GMT, geometric mean titer.
Estimated protection (95% confidence intervals) conferred by a single dose of killed oral cholera vaccine, by study site and duration.
Similar articles
-
Cordero De Los Santos L, Feris-Iglesias J, Aloysia D'Cor N, Midde VJ, Patnaik BN, Thollot Y, Rasuli A, Desauziers E. Cordero De Los Santos L, et al. Hum Vaccin Immunother. 2018 Jun 3;14(6):1403-1411. doi: 10.1080/21645515.2018.1430540. Epub 2018 Feb 22. Hum Vaccin Immunother. 2018. PMID: 29470934 Free PMC article. Clinical Trial.
-
Capeding MRZ, Gonzales MLAM, Dhingra MS, D'Cor NA, Midde VJ, Patnaik BN, Thollot Y, Desauziers E. Capeding MRZ, et al. Hum Vaccin Immunother. 2017 Oct 3;13(10):2232-2239. doi: 10.1080/21645515.2017.1342908. Hum Vaccin Immunother. 2017. PMID: 28910563 Free PMC article. Clinical Trial.
-
Raghava Mohan V, Raj S, Dhingra MS, Aloysia D'Cor N, Singh AP, Saluja T, Kim DR, Midde VJ, Kim Y, Vemula S, Narla SK, Sah B, Ali M. Raghava Mohan V, et al. PLoS One. 2019 Jun 18;14(6):e0218033. doi: 10.1371/journal.pone.0218033. eCollection 2019. PLoS One. 2019. PMID: 31211792 Free PMC article. Clinical Trial.
-
A review of the current status of enteric vaccines.
Levine MM, Noriega F. Levine MM, et al. P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.
-
Bi Q, Ferreras E, Pezzoli L, Legros D, Ivers LC, Date K, Qadri F, Digilio L, Sack DA, Ali M, Lessler J, Luquero FJ, Azman AS; Oral Cholera Vaccine Working Group of The Global Task Force on Cholera Control. Bi Q, et al. Lancet Infect Dis. 2017 Oct;17(10):1080-1088. doi: 10.1016/S1473-3099(17)30359-6. Epub 2017 Jul 17. Lancet Infect Dis. 2017. PMID: 28729167 Free PMC article. Review.
Cited by
-
Ateudjieu J, Yakum MN, Goura AP, Tembei Ayok M, Guenou E, Kangmo Sielinou CB, Kiadjieu FF, Tsafack M, Douanla Koutio IM, Tchio-Nighie KH, Tchokomeni H, Ntsekendio PN, Sack DA. Ateudjieu J, et al. BMC Public Health. 2022 Feb 5;22(1):238. doi: 10.1186/s12889-022-12610-5. BMC Public Health. 2022. PMID: 35123444 Free PMC article.
-
Oral killed cholera vaccines for preventing cholera.
Saif-Ur-Rahman KM, Mamun R, Hasan M, Meiring JE, Khan MA. Saif-Ur-Rahman KM, et al. Cochrane Database Syst Rev. 2024 Jan 10;1(1):CD014573. doi: 10.1002/14651858.CD014573. Cochrane Database Syst Rev. 2024. PMID: 38197546 Free PMC article. Review.
-
The case for ring vaccinations with special consideration of oral cholera vaccines.
Deen J, von Seidlein L. Deen J, et al. Hum Vaccin Immunother. 2018;14(8):2069-2074. doi: 10.1080/21645515.2018.1462068. Epub 2018 May 11. Hum Vaccin Immunother. 2018. PMID: 29630444 Free PMC article.
-
Fakoya B, Hullahalli K, Rubin DHF, Leitner DR, Chilengi R, Sack DA, Waldor MK. Fakoya B, et al. mBio. 2022 Apr 26;13(2):e0053922. doi: 10.1128/mbio.00539-22. Epub 2022 Apr 7. mBio. 2022. PMID: 35389261 Free PMC article.
-
Estimating cholera incidence with cross-sectional serology.
Azman AS, Lessler J, Luquero FJ, Bhuiyan TR, Khan AI, Chowdhury F, Kabir A, Gurwith M, Weil AA, Harris JB, Calderwood SB, Ryan ET, Qadri F, Leung DT. Azman AS, et al. Sci Transl Med. 2019 Feb 20;11(480):eaau6242. doi: 10.1126/scitranslmed.aau6242. Sci Transl Med. 2019. PMID: 30787170 Free PMC article.
References
-
- UNICEF, WHO. Progress on sanitation and drinking water—2015 update and MDG assessment Available from http://files.unicef.org/publications/files/Progress_on_Sanitation_and_Dr.... Accessed 30 October 2017.
-
- World Health Organization. Cholera, 2013. Wkly Epidemiol Rec 2014; 89: 345–55. - PubMed
-
- Clemens JD, Harris JR, Sack DA et al. . Field trial of oral cholera vaccines in Bangladesh: results of one year of follow-up. J Infect Dis 1988; 158:60–9. - PubMed
-
- Clemens JD, Sack DA, Harris JR et al. . Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990; 335:270–3. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical